



Treatment of *Mycobacterium tuberculosis*: A Persisting Challenge

Guest Editors:

Dr. Neeraj Dhar

Vaccine and Infectious Disease
Organization, University of
Saskatchewan, Saskatoon, SK,
Canada

Dr. Shulin Qin

Division of Pulmonary, Allergy
and Critical Care Medicine,
Department of Medicine, School
of Medicine, University of
Pittsburgh, Pittsburgh, PA, USA

Deadline for manuscript
submissions:

closed (30 June 2022)

Message from the Guest Editors

Antibiotics targeting *Mycobacterium tuberculosis* have been around for more than 75 years now. However, treatment of tuberculosis is extremely challenging and mandates the use of multiple drugs in a strict regimen to effect a successful cure.

The main requisites for a candidate new drug against TB are

Good cidal activity to be able to rapidly reduce the bacterial population and thereby minimize further transmission;

(Better?) activity against the bacteria during the persistent phase to ensure quick and complete cure;

Low frequency of drug resistance.

Targeting persistent subpopulations is extremely crucial if we are to achieve the goal of shortening the duration of TB therapy. Recent advances in single-cell biology and imaging have helped us to gain an understanding of some of the challenges to achieving these goals. This Special Issue seeks manuscript submissions that expand our understanding of the mechanisms *M. tuberculosis* adopts to survive and persist against antibiotics. Submissions on approaches to identify compounds that can specifically target these persisting subpopulations are especially encouraged.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi